Most pharma companies spend 6–12 months remediating batch record 483 observations — navigating data integrity gaps, missing signatures, and incomplete review documentation. ClearBatch deploys in weeks and closes findings at the source.
Time matters. Companies contacted by the FDA have typically received their 483 within the last 30–90 days. Don't let remediation drag into the next inspection cycle.
These aren't abstract compliance failures. They're the specific observations FDA investigators cite in 483s — and they're almost always preventable with the right systems in place.
Batch records altered after the fact, audit trail gaps, test results recorded without contemporaneous documentation, or data entered by someone other than the analyst who performed the work.
21 CFR 211.68 / 211.192 — Most cited in CDER Warning Letters
Steps completed but not signed by a second reviewer. Electronic systems that allow skip-signing. QA disposition signatures missing or undated. Required review documentation unsigned at time of activity.
21 CFR Part 11 / 211.68(b) — Electronic Records & Signatures
Batch record review completed but deviations not formally documented. Reviewer notes on paper with no traceability. Critical review steps skipped or marked N/A without justification.
21 CFR 211.192 — Production Record Review
Out-of-specification results investigated but root cause not identified. CAPA documentation incomplete. Repeat deviations with no systemic corrective action. Investigation timelines exceeded with no justification.
21 CFR 211.192 / 211.198 — Failure Investigation
The reality: These observations aren't caused by careless teams. They're caused by systems that require humans to manually track hundreds of data points per batch, sign every entry, and document every decision — across paper records, spreadsheets, and disconnected software. The process was designed to fail. ClearBatch replaces it.
Each 483 finding type maps to a specific gap in your current process. ClearBatch closes them at the system level — not through procedural workarounds that need to be audited again.
Manual data entry, transcription errors, untracked edits, and audit trail gaps create the conditions for 483 observations and, in serious cases, warning letters.
Every data entry, review action, and system change is timestamped and immutably logged. No retroactive edits. No unsigned entries. Complete electronic audit trail from upload to disposition — ready for FDA inspection on demand.
Paper-based or hybrid systems allow steps to proceed without required second-reviewer signatures. Electronic workarounds with shared logins destroy 21 CFR Part 11 compliance.
Role-based access controls enforce who can sign what and when. Electronic signatures are unique to each user, date-stamped, and can't be bypassed. Required review steps can't be skipped — the workflow won't progress without them.
Reviewers complete the work but documentation is scattered — some in the batch record, some in emails, some in a QMS that's disconnected from the actual review process.
AI flags only the items needing human judgment. Every flag, every reviewer note, every disposition decision is captured in the same system — linked to the exact batch record entry it references. Nothing lives in email. Nothing lives in a spreadsheet.
When deviations occur, investigation documentation is often incomplete, delayed, or disconnected from the original batch record evidence that triggered the deviation.
ClearBatch auto-detects deviations, flags OOS/OOT results, and generates structured investigation documentation with regulatory citations. CAPA recommendations are linked directly to the evidence — no more disconnected paperwork chains.
Legacy QMS systems require extensive IT infrastructure, complex integrations, and months of custom configuration. ClearBatch is web-based, pre-validated for pharma environments, and ships with all the compliance documentation your Quality Unit needs out of the box — IQ/OQ/PQ templates, validation master plan, and traceability matrices. We don't go live until your team is confident. But we don't make you wait 9 months to get there.
Aggregated from pilot deployments across QC teams processing small molecule and biologics batches.
vs. 4–6 hours manual review per batch
Across all parameter types and product families
End-to-end batch release cycle time
Electronic records and signatures that satisfy Part 11 requirements: unique user authentication, controlled access, immutable audit trails, date-stamped e-signatures, and system validation documentation.
Every action logged with user identity, timestamp, and system state. No retroactive edits possible. Audit trail exportable for inspection readiness. Designed to withstand an FDA investigator's scrutiny on day one.
Role-based signature workflows that enforce required reviews before batch disposition. Every signature linked to a unique user account — no shared logins, no delegation without traceability.
IQ/OQ/PQ protocols, validation master plan, and traceability matrices provided as part of deployment. Your Quality Unit doesn't start from scratch — we ship the documentation the FDA expects to see.
ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate) enforced at the system level. Data integrity isn't a procedure at ClearBatch — it's an architectural constraint.
Batch record review, deviation management, and CAPA documentation workflows are designed around the cGMP requirements in Parts 210 and 211. Regulatory citations are embedded in every flagged deviation.
Every week without a remediation plan extends your regulatory exposure and increases the likelihood of escalation to a Warning Letter. A 30-minute call is all it takes to understand whether ClearBatch fits your situation.
No commitment. No sales pressure. Just an honest conversation about whether we're the right fit for your remediation timeline.